Britain does not lack research output. It lacks a reliable mechanism for turning more of that research into large, domestically financed companies. That distinction is the useful investment insight behind Gordon Brown’s argument that higher “innovation intensity” could eventually add £150 billion to annual national income and leave households £5,000 better off.
Those numbers are Brown’s calculations, not an official forecast. They should be treated as a scenario illustrating the potential productivity prize, not as a guaranteed return from higher research spending. The evidence is stronger on the diagnosis: Britain produces world-class science but often loses ownership, financing and manufacturing value as companies scale.
The research base is already substantial
Brown points to four UK universities in the global top 10 and a research system that produces 6% of world papers, nearly 9% of citations and 12% of the most highly cited work despite the country having less than 1% of global population. Those figures describe scientific influence, not commercial capture.
Official data provide a financial baseline. The [Office for National Statistics](https://www.ons.gov.uk/economy/governmentpublicsectorandtaxes/researchanddevelopmentexpenditure/bulletins/ukgrossdomesticexpenditureonresearchanddevelopment/latest) estimated that £79.4 billion was spent on R&D performed in the UK in 2024, up £3.6 billion from 2023. Business-performed R&D was £55.6 billion, up 4.5% in current prices.
The arithmetic matters. Business R&D already represents roughly 70% of total UK-performed R&D, so the problem cannot be reduced to government laboratories or university grants. The commercial system must improve the conversion rate from research to recurring revenue, productive capital and exportable intellectual property.
Productivity is the economic bridge
Higher R&D raises living standards only if it improves output per hour, creates scalable products or reduces the cost of delivering services. [Resolution Foundation’s third-quarter 2026 macro outlook](https://www.resolutionfoundation.org/publications/the-macroeconomic-policy-outlook-q3-2026/) estimated that output per hour in the second quarter was about 5% below the level implied by the pre-pandemic Office for Budget Responsibility forecast. It translated that shortfall into roughly £150 billion of lost annual output, or £4,500 per worker.
That comparison does not validate Brown’s separate £150 billion estimate, even though the totals are similar. One measures a productivity gap against an earlier forecast; the other is a scenario tied to stronger innovation. The coincidence is still instructive: small persistent differences in productivity compound into very large changes in national income.
AI may improve the trajectory, but adoption is not automatic. New software must be integrated into workflows, workers need complementary skills and organizations must redesign processes. Spending on models or data centers can lift measured investment before it produces cash savings. Investors should therefore distinguish between innovation inputs—R&D, patents and venture funding—and outputs such as revenue per employee, export share, margins and new-company survival.
Britain’s scale-up leakage
Brown argues that the United States has roughly twice as many $1 billion companies per capita and nearly three times as many worth more than $10 billion. He also says about three-quarters of venture-capital investment in UK scale-ups comes from overseas.
Foreign capital is not inherently negative. It can finance faster expansion and connect companies to global customers. The problem arises when financing is paired with an early sale, relocation of decision-making or migration of intellectual property. Britain may then retain high-quality research jobs while losing a larger portion of long-duration equity value, procurement and tax revenue.
The financing gap is partly structural. Pension funds and insurers have long-duration liabilities but face governance, liquidity and fee constraints that can discourage allocations to venture and growth equity. Smaller funds may lack the expertise to underwrite highly technical businesses. Public policy can reduce those frictions, but it cannot turn weak companies into good investments.
That is why proposals involving the British Business Bank and National Wealth Fund need explicit return disciplines. Public money can crowd in private capital, absorb early infrastructure risk or anchor regional clusters. It should not shield investors from normal commercial failure or preserve companies with no credible path to scale.
Clusters need more than slogans
Research for Brown’s conference identified 127 innovation clusters across the UK. A cluster becomes economically meaningful when universities, specialized labor, suppliers, patient capital and customers reinforce one another. Each element has a different time horizon: laboratories may take years to build, skills pipelines take longer, while venture rounds can disappear quickly when markets tighten.
Policy therefore needs continuity more than a single “moonshot.” Stable R&D credits, predictable planning rules, research infrastructure and procurement pathways can improve expected returns. Devolution can help mayors coordinate transport, training and local institutions, but national markets and global distribution remain essential.
For public-market investors, the most relevant beneficiaries are not necessarily the earliest startups. Listed engineering groups, testing providers, data-center operators, software suppliers, life-science landlords and specialist lenders may capture demand as clusters expand. The counterargument is that generous incentives can inflate costs or subsidize activity that would have happened anyway.
A measurable scorecard
The £5,000-per-household claim is too broad to trade on. A better scorecard would track business R&D in real terms, domestic growth-capital participation, the number of UK companies crossing £1 billion and £10 billion valuations without relocating, high-value exports, productivity by adopting industry and the share of intellectual property retained in Britain.
The next policy plan should also state how success will be evaluated and over what period. Innovation benefits arrive unevenly, while fiscal costs arrive immediately. Transparent milestones would let investors separate a durable industrial strategy from a temporary subsidy cycle.
Britain’s opportunity is real because the research base is already in place. The decisive question is whether capital, skills and procurement can keep promising firms growing at home long enough for the country—and its investors—to retain more of the resulting value.